Skip to content

Fertility Preservation in Young Women With Cancer

Fertility Preservation in Young Women With Cancer: an International Registration Study From the International Network on Cancer, Infertility and Pregnancy (INCIP)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02878434
Enrollment
2000
Registered
2016-08-25
Start date
2017-05-23
Completion date
2032-07-31
Last updated
2020-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer, Fertility

Keywords

Cancer, Fertility, Pregnancy, Chemotherapy, Radiotherapy, Long term, Follow up

Brief summary

The researchers aim to record the incidence, treatment and long term follow up of fertility preserving cancer treatment. Both the oncological and fertility outcome are recorded. Study population: All patients with a cancer for whom a fertility preserving cancer treatment is applied. The results of the study population are compared to young women undergoing standard cancer treatment.

Detailed description

Cancer is the second leading cause of death during the reproductive years. The long term survival improves for most cancers, reaching 80% for pediatric cancer and more than 70% for cancers in adults between 20 and 49 years of age. Early detection and improvements in cancer treatment contribute to these figures. As a result, quality of life of which preservation of fertility is one aspect, becomes more important. Fertility may however be influenced by surgery and by the gonadotoxic effects of chemo and/or radiotherapy. Therefore, fertility sparing treatments are offered to young patients in order to maintain the wish to conceive after cancer treatment. This however is associated with deviation of standard treatment and many different strategies are applied among different centers. In addition, there is a lack of studies investigating the oncological safety of these fertility sparing treatment protocols. The results of this study will enable us to better inform clinicians and patients on the efficacy of fertility sparing cancer treatment. Objective: To record the incidence, treatment and long term follow up of fertility preserving cancer treatment. Both the oncological and fertility outcome are recorded. Study design: International multicentre prospective observational trial Study population: All patients with a cancer for whom a fertility preserving cancer treatment is applied. The results of the study population are compared to young women undergoing standard cancer treatment. Main study parameters/endpoints: Registration of cancer diagnosis, treatment and outcome. Both the oncologic and fertility outcome is registered. All patients receive fertility sparing cancer treatment on their specific request.

Interventions

None listed

Sponsors

NKI-AvL
CollaboratorUNKNOWN
Medical University of Vienna
CollaboratorOTHER
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
CollaboratorOTHER
Oslo University Hospital
CollaboratorOTHER
Haukeland University Hospital
CollaboratorOTHER
N.N. Blokchin NMRCO
CollaboratorUNKNOWN
University Hospital, Gasthuisberg
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
0 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* Young women who want to preserve their fertility during cancer treatment. Patients need to give their signed and written informed consent to participate in the study.

Exclusion criteria

* Mentally disabled or significantly altered mental status that would prohibit the understanding and giving of informed consent

Design outcomes

Primary

MeasureTime frameDescription
Fertility Outcome10 yearspregnancy rate

Secondary

MeasureTime frameDescription
Oncological Outcome5 yearsRecurrence of cancer

Countries

Belgium, Netherlands

Contacts

Primary ContactKatrien Van Tornout
katrien.vantornout@uzleuven.be+3216342876

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026